近期,全球多肽和寡核苷酸(TIDES)领域迎来系列进展。诺和诺德(Novo Nordisk)公布了CagriSema用于治疗2型糖尿病的3期临床试验结果,该药在第68周时在糖化血红蛋白(HbA1c)降低和体重减轻方面均优于2.4 mg的司美格鲁肽,且这一优势在试验评估的所有剂量组中均有体现。辉瑞(Pfizer)公布了旗下GLP-1受体激动剂(GLP-1 RA)PF-08653944用于无2型糖尿病...
Source Link近期,全球多肽和寡核苷酸(TIDES)领域迎来系列进展。诺和诺德(Novo Nordisk)公布了CagriSema用于治疗2型糖尿病的3期临床试验结果,该药在第68周时在糖化血红蛋白(HbA1c)降低和体重减轻方面均优于2.4 mg的司美格鲁肽,且这一优势在试验评估的所有剂量组中均有体现。辉瑞(Pfizer)公布了旗下GLP-1受体激动剂(GLP-1 RA)PF-08653944用于无2型糖尿病...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.